Kowa Pharmaceuticals America,Inc. Announces Publication of Phase 3 Data Supporting FDA Approval of SEGLENTIS®(celecoxib 56-mg and tramadol hydrochloride 44mg)CI-V as an Efficacious Alternative for Moderate-to-Severe Acute Pain in Appropriate Patients  https://t.co/WB4tHU0p9Q  https://t.co/DeUCbwEpIs